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PDGF receptorThe dimerization and auto-transphosphorylation of platelet-derived growth factor receptor (PDGFR) upon
engagement by platelet-derived growth factor (PDGF) activates signals promoting the mitogenic response of
hepatic stellate cells (HSCs) due to liver injury, thus contributing to the development of hepatic ﬁbrosis. We
demonstrate that the tyrosine phosphatases Src homology 2 domain-containing phosphatase 1 and 2 (SHP-1
and SHP-2) act as crucial regulators of a complex signaling network orchestrated by PDGFR activation in a
spatio-temporal manner with diverse and opposing functions in HSCs. In fact, silencing of either phosphatase
shows that SHP-2 is committed to PDGFR-mediated cell proliferation, whereas SHP-1 dephosphorylates PDGFR
hence abrogating the downstream signaling pathways that result in HSC activation. In this regard, SHP-1 as an
off-switch of PDGFR signaling appears to emerge as a valuable molecular target to trigger as to prevent HSC
proliferation and the ﬁbrogenic effects of HSC activation. We show that boswellic acid, a multitarget compound
with potent anti-inﬂammatory action, exerts an anti-proliferative effect on HSCs, as in other cell models, by
upregulating SHP-1 with subsequent dephosphorylation of PDGFR-β and downregulation of PDGF-dependent
signaling after PDGF stimulation. Moreover, the synergism resulting from the combined use of boswellic acid
and imatinib, which directly inhibits PDGFR-β activity, on activated HSCs offers new perspectives for the
development of therapeutic strategies that could implementmolecules affecting diverse players of thismolecular
circuit, thus paving the way to multi-drug low-dose regimens for liver ﬁbrosis.
© 2013 Published by Elsevier B.V.1. Introduction
Liver ﬁbrosis is a dynamic and reversible process which occurs in
response to acute or chronic liver injury and is characterized by
accumulation of extracellular matrix (ECM) proteins [1,2]. Persistence
of liver damage with advanced liver ﬁbrosis may lead to life-
threatening conditions, such as portal hypertension, cirrhosis and
ultimately hepatocellular carcinoma. Major players in the deposition of
ECM proteins are hepatic stellate cells (HSCs), which upon liver damage
are activated by several inﬂammatory cytokines, including growth
factors, interleukins, chemokines and adipokines, hence developing a
myoﬁbroblast-like phenotype with proliferative, contractile, pro-
inﬂammatory and ﬁbrogenic properties [3]. Among these cytokines, the
platelet-derived growth factor (PDGF), which is mainly produced by
Küpffer cells, acts as the most potent mitogen and effective chemotactic
factor for HSCs [4,5] by engaging its cognate receptor (PDGFR), a+39 049 8073310.
o), annamaria.brunati@unipd.it
vier B.V.member of the receptor tyrosine kinase (RTK) family. This event causes
the dimerization, the subsequent activation of the kinase domain of
PDGFR and the autophosphorylation of speciﬁc tyrosine residues in its
cytosolic tail, thereby forming a phosphotyrosine (pTyr)-based platform
for proteins bearing Src homology 2 (SH2) domains, which ultimately
contribute to the activation the downstream signaling pathways [6,7].
To date, although there exist no agents approved as antiﬁbrotic drugs,
molecules already employed in the treatment of other diseases and,
albeit not exclusively, inhibiting the kinase activity of PDGFR such as
imatinib, nilotinib, sorafenib, and sunitinib, have exhibited anti-ﬁbrotic
activity [8–11]. It is to be underlined that the signals downstream of
PDGFR activation are not only triggered by the kinase activity of the
receptor but also governed and modulated by the action of protein
tyrosine phosphatases (PTPs), whose role, albeit recognized as crucial
in the regulation of signal transduction of various biological models, is
still elusive in HSCs.
In this respect, PTPs not only turn off pTyr-dependent signaling, but
can also contribute to the ﬁne tuning, and consequently to the
speciﬁcity of signaling cascades [12], these two different functions
being well exempliﬁed by the two members of the ubiquitous Src
homology 2 domain-containing phosphatase (SHP) family SHP-1 and
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often exert opposing biologic functions. In fact, whilst SHP-1 acts as a
negative signal transducer involved in the downregulation of several
RTKs, including PDGFR, the insulin receptor, the EGF receptor and
VEGF receptor type 2, SHP-2 is a positive mediator of the Ras-
extracellular signal-regulated kinase 1/2 (Erk 1/2) and Akt signaling
pathways [15–18], thereby the former PTP impairing and the latter
promoting cell growth and proliferation [8–10,19]. The regulation of
these phosphatases is strictly dependent upon its multi-modular
structure consisting of a central catalytic domainﬂanked by two tandem
SH2 domains at the N-terminus and a C-terminal regulatory tail as well
as phosphorylation at critical amino acid residues. Whilst the more
N-terminal SH2 domain maintains both phosphatases in a closed
inactive conformation by occupying the catalytic cleft and preventing
the substrate access, engagement of the SH2 domains by tyrosine
phosphorylated partner proteins disrupts the inhibitory intramolecular
interactions with subsequent phosphorylation at C-terminal tyrosine
residues, both events leading to full activation [20–24]. Importantly,
the catalytic activity of SHP-1 can also be suppressed by phosphory-
lation at Ser591 by PKC or MAPK, which mechanism of inhibition has
not been described for SHP-2 [25].
The aim of this work was to attempt to give a contribution to the
unexplored role of these two PTPs and their relation to PDGFR activation
in HSCs, and to assess whether they may represent valuable targets for
drug discovery to establish new therapeutic strategies against liver
ﬁbrosis.
Here, we demonstrate that, although SHP-2 and SHP-1 are both
involved in the regulation of PDGFR-dependent proliferative signals in
HSCs, SHP-1 acts as a brake on HSC proliferation by dephosphorylating
PDGFR-β and this effect can be enhanced bymolecules that stimulate its
expression (there are no known stimulators of SHP-1 activity), such as
boswellic acid (BA), a compound present in the resin of Boswellia
serrata, a plant used in Ayurvedic medicine in the treatment of a
number of inﬂammatory diseases [26]. Notably, imatinib, the pro-
totypical tyrosine kinase inhibitor that directly inhibits PDGFR activity
and administered in certain types of cancer, and BA exhibit a striking
synergism when used in association, opening new possibilities of
designing more potent anti-proliferative drug combinations to effec-
tively block HSC proliferation and prevent ﬁbrogenesis.2. Materials and methods
2.1. Materials and chemicals
Unless otherwise speciﬁed, reagents were obtained from Sigma
(St. Louis, MO). Stealth™ RNAi for SHP-1 and SHP-2, Stealth™ RNAi
Negative Control Duplexes, and Lipofectamine RNAiMAX Reagent were
purchased from Invitrogen (Carlsbad, CA). FTY720 was purchased from
Alexis (CH-4415 Lausen, Switzerland). Enhanced chemiluminescent
detection system (ECL) was purchased from Pierce (Thermo Fisher
Scientiﬁc, Rockford, IL USA). Protease inhibitor cocktail (cOmplete
tablets) and Cell Proliferation ELISA, BrdU (chemiluminescent) were
purchased from Roche Diagnostics (Manheim, Germany). 8-Hydroxy-
7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-
87877) was purchased from Millipore Corporation (Billerica, USA).
Sodium stibogluconate and boswellic acid (cod. A9855) were from
Sigma (St. Louis, MO). Antibodies were obtained as follows: anti-
pPDGFR-β, anti-PDGFR-β, anti-pAkt, anti-Akt, and anti-SHP-2 were
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); anti-pERK1/2,
anti-ERK, and anti-pY580-SHP-2, were from Cell Signaling Technology,
Inc. (Danvers, MA); anti-phosphotyrosine (PY-20) monoclonal
antibody, anti-SHP-1 was from Millipore Corporation (Billerica, USA);
anti-pS591-SHP-1, and anti-pY536 SHP-1 were from ECM Biosciences
(Versailles, KY); and anti-GAPDH, anti-α-SMA, anti-GFAP, and anti-β-
actin antibodies were from Sigma-Aldrich Inc. (St. Louis, MO).2.2. Cell isolation and culture
HSCs were isolated from the livers of normal male Wistar rats. All
animals were purchased from Charles River Laboratories and housed
in the Animal Research Facility of the Molecular Medicine Department,
in accordance with the National Institute of Health guidelines for the
care of laboratory animals. They were maintained under a 12-hour
light–dark cycle and given rat chow and water ad libitum. According
to the method described in Zhang et al. [27], livers were perfused with
a calcium-free buffer solution to wash out the blood, subsequently
with a wash solution (calcium-free solution with CaCl2 0.294 g/l,
MgSO4 0.097g/l) and ﬁnally incubated in a digestion buffer (collagenase
0.6g/l in Gey's Balanced Salt Solution with Ca2+ and Mg2+, pH7.5) for
1 h (37 °C, CO2 5%) to digest the extracellular matrix. The organs were
cut into small pieces and subjected to homogenization to produce a
single cell-suspension, which was centrifuged at 1450 g for 18min in a
12% (wt/vol) Nycodenz density gradient to obtain a pure HSC fraction.
Both the number and viability of HSCs were determined using the
trypan blue dye exclusion test. HSCs were collected and washed with
Hank's balanced salt solution and resuspended at a concentration of
1 × 105 cells/ml, in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 20% fetal bovine serum (FBS), 100 U/ml penicillin
and 100 μg/ml streptomycin and cultured on collagen type I coated
well-plates (10 μg/ml) in a 5% CO2-humidiﬁed atmosphere. After
passage 2, FBS was diluted to 10%. All experiments were performed
using HSCs between passages 3 and 8.
2.3. Cell proliferation assay and calculation of drug synergism
Proliferation assays were performed by using Roche Cell
Proliferation ELISA, BrdU (chemiluminescent). Brieﬂy, 7.5 × 103 cells
were seeded on 96-well ﬂat bottom microplates and incubated in
DMEM medium alone for 24 h to stop cell growth. Cells were
preincubated at time points as indicated in the Results in the absence
or presence of NSC-87877, SSG, BA and imatinib, and then treated
with PDGF-BB (10 ng/ml) at different incubation times. HSCs were
labeled with 10 μM BrdU 10 h before each single incubation time
point. The following treatment was carried out according to the
manufacturer's guidelines. The microplates were then washed three
times with washing solution and 100 μl substrate solution was added
and incubated for 5 min. Absorbance of the samples was measured
using a luminometer. To evaluate the effects of BA and imatinib in
combination, we calculated the combination index (CI), which turns
out to be less than 1, equal to 1 and more than 1 in the case of synergy,
additive effect and antagonism, respectively, by using the CompuSyn
software [28].
2.4. Western blot analysis
Cells were seeded on 24-well plates, cultured in DMEM medium
supplemented with 10% FBS to conﬂuence and then incubated for
24 h in DMEM medium alone. Cultured cells were subjected to various
stimuli, as described in the ﬁgure legends, detached by scraping and
centrifuged at 1200rpm for 5min. Cells were resuspended and quickly
lysed in a buffer containing 62 mM Tris/HCl solution (pH 6.8), 5%
glycerol, 0.5% SDS, and 0.5% β-mercaptoethanol. Samples were run in
10% SDS-PAGE and transferred to nitrocellulose membranes. After
treatment with 3% bovine serum albumin for 1 h, membranes were
incubatedwith the appropriate antibodies overnight and, afterwashing,
with secondary horseradish peroxidase-conjugated polyclonal antibody
for 30min. Bound antibodieswere detected by the ECL detection system
(Pierce, on a Kodak Image Station 440CF and visualized with Kodak 1D
Image software (Rochester, NY). Membranes, when required, were
reprobed with other primary antibodies after stripping with 0.1 M
glycine (pH 2.5), 0.5 M NaCl, 0.1% Tween 20, 1% β-mercaptoethanol
and 0.1% NaN3 for 2×10min.
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1 × 106 HSCs, as such or incubated with different stimuli, were
disrupted on ice by sonication in 1 ml isotonic buffer containing
50 mM Tris/HCl pH 7.5, 0.25 M sucrose, 1 mM diamide, 1 mM
orthovanadate, phosphatase inhibitor cocktail 2 and 3 (Sigma), and
protease inhibitor cocktail (Roche). Homogenates were centrifuged for
10 min at 10,000 g, in order to separate the particulate fraction
containing nuclei, and other cellular particles as described in [29]. The
supernatant was further centrifuged for 1 h at 105,000 g to separate
cytosol from microsomes. Protein concentration was determined by
the Bradford method. The microsomes were either subjected to
Western blot analysis with the appropriate antibodies or tyrosine
phosphatase activity assays after removal of the phosphatase inhibitors.2.6. Treatment of microsomes with λPPase and GST-SHP-1/SH2 domain
Microsomes (50 μg) were incubated in the absence or presence of
λPPase (500 U) or recombinant GST-SHP-1/SH2 domain (10 μg) in
50mM Tris/HCl pH 7.5, 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% BRIJ
35, 2mMMnCl2, protease inhibitors, for 45min at 30 °C, as reported in
[29]. After each treatment, the samples were centrifuged for 1 h at
105,000 g to separate the pellet (P) from the soluble fraction (S). The
samples were subjected to Western blot analysis with anti-SHP-2 and
anti-SHP-1 antibodies.2.7. Immunoprecipitation
HSCs were suspended for 1 h at 4 °C in 0.5 ml of buffer containing
20 mM Tris–HCl, pH 7.4, 10% glycerol, 1 mM EGTA, 1 mM EDTA,
150mMNaCl, 1mMsodiumorthovanadate, 1mMdiamide, phosphatase
inhibitor cocktails 2 and 3, protease inhibitor cocktail and 1% Triton
X-100. After centrifugation, equal aliquots of supernatants were further
supplemented with 0.5ml of the same buffer without Triton X-100 and
incubated overnight in the presence of anti-PDGFR-β antibody. The
immune complexes were collected with protein A-agarose and washed
three times in 50 mM Tris–HCl (pH 7.5), 1 mM orthovanadate and
protease inhibitor cocktail. The immunoprecipitates were either
subjected to Western blot analysis with the appropriate antibodies or
tyrosine phosphatase activity assays after removal of the phosphatase
inhibitors.2.8. RNA interference
SiRNA transfections into HSCs were performed using the
Lipofectamine RNAiMAX Reagent as recommended by the manu-
facturer. Brieﬂy, the day before transfection, cells were diluted with
fresh medium without antibiotics and transferred to six-well plates
(40% conﬂuent). HSCs were transfected with 40nM of siRNA duplexes
(control or against SHP-1 or SHP-2). After 48 h cells were treated with
PDGF-BB and subject to the treatments as described in the Results.2.9. [32P]-phospho band 3 preparation
Band 3 was phosphorylated by incubating erythrocyte ghosts
(15 μg) at 30 °C with the tyrosine kinases Syk and Lyn in the presence
of [γ32P]ATP as elsewhere described [30]. After 10-min incubation, the
sample was centrifuged at 14,000 g and the pellet was washed 3 times
with 25 mM Tris, pH 8.0, 1 mM EDTA, 0.02% NaN3, 10% glycerol,
10 mM β-mercaptoethanol, 10 mg/ml leupeptin, and 50 mM
phenylmethylsulphonyl ﬂuoride (B3 buffer) and then resuspended in
the same buffer for the phosphatase activity assay.2.10. Tyrosine phosphatase activity assay
Tyrosine phosphatase activity was tested by adding 10 μg of the
microsomal fraction suspended in B3 buffer supplemented with 0.1%
Nonidet P-40 as well as SHP-2 or SHP-1 immunoprecipitates in the
presence of 0.3 μg of [32P]phospho-band 3 as a substrate. After 10-min
incubation at 30 °C, the assays were stopped and subjected to SDS-
PAGE. The extent of [32P]phospho-band 3 dephosphorylation was
evaluated either by analysis on a Packard Cycloneor by autoradiography
and, after excision of the band 3, by liquid scintillation counting.
2.11. Statistical analysis
Data are presented as mean ± SD and compared using one-way
analysis of variance (ANOVA) followed by Student's t test. A
P-value b 0.05 was considered as statistically signiﬁcant. All statistics
were performed using GraphPad Prism (version 4) statistical software
(GraphPad Software; San Diego, CA).
3. Results
3.1. SHP-2 and SHP-1 are activated in a different spatiotemporal manner in
HSCs upon PDGF-BB stimulation
The level of expression of SHP-1 and SHP-2 was ﬁrst evaluated by
Western blot analysis performed on rat HSCs undergoing 5 to 15days'
culture activation and subsequently after stimulation with PDGF-BB in
serum-starved HSCs compared to quiescent HSCs. Fig. 1A shows that
both PTPs were present in HSCs in the aforementioned conditions and
that SHP-2 expression only was increased by HSC culture activation by
~40% and irresponsive to PDGF-BB as compared with activated HSCs.
The culture activation of and the effect of PDGF-BB stimulation on
HSCs were monitored by the change in the expression of Glial Fibrillary
Acidic Protein (GFAP) and α-SMA [31] by Western blot analysis. In
parallel, the activation state of SHPs was checked in PDGF-BB-
stimulated HSCs by Western blot analysis on whole cell lysates with
antibodies directed against SHP-2 phospho-Y580 (pY580), indicative
of SHP-2 activation [22–24] as well as SHP-1 phospho-S591 (pS591)
and phospho-Y536 (pY536), suggestive of SHP-1 inhibition and
activation, respectively [24], at discrete time points. As described in
Fig. 1B, within a 12 h time-frame, the two PTPs became tyrosine
phosphorylated at different time points, SHP-2 being early activated
(5 min) and peaking between 30 min and 1 h and thereafter slowly
declining; in contrast, SHP-1 underwent later activation (1 h), which
was fully achieved at 6–12 h, with a trend inversely related to that
of inhibitory serine phosphorylation. In the wider scenario of intra-
cellular signaling, we also analyzed the signals generated by PDGF-BB
stimulation, and particularly the phosphorylated forms of PDGFR-β
(pPDGFR) as well as of ERK1/2 (pErk1/2) and Akt (pAkt), the latter
two being sensitive indices of the transmission of proliferative and
survival signals from membrane-bound receptors, by Western blot
analysis [32–34]. pPDGFR-β reached the maximum response within
5 min, declining after 6 h in parallel with SHP-1 activation, pERK1/2
and pAkt in turn increasing later than the phosphorylated receptor
and conﬁrming that their activation occurs far downstream of the
receptor itself [32–34]. Because SHP-2 and/or SHP-1 are known to be
recruited to the plasma membrane by interaction of their SH2 domains
to tyrosine phosphorylated partner proteins upon activation of growth
factor receptors, with subsequent full activation of the PTPs, we ﬁrst
searched for such activated forms at the plasma membrane of HSCs at
different time points.
As shown in Fig. 2A, both phosphatases proved to be associatedwith
cellular membranes (microsomes), with the activated forms displaying
a trend similar to the protein level. We then attempted to assess
whether the two PTPs were recruited to the microsomes through the
interaction of their SH2 domains with tyrosine phosphorylated proteins
A B
Fig. 1. Effect of PDGF-BB stimulation on the protein level and activation state of SHP-2 and SHP-1 inHSCs. (A)Whole cell lysates from quiescent (cultured for 1day), activated (cultured for
5 and 15 days) and PDGF-BB-stimulated (24 h and 48 h) HSCs underwent Western blot analysis with antibodies directed against SHP-2, SHP-1, GFAP (marker for resting HSCs), α-SMA
(marker for activated and PDGF-BB-stimulated HSCs) and GAPDH (marker for protein loading). Densitometric analysis (arbitrary units) of the SHP-2 and SHP-1 bands is shown. Data are
mean±SD from 4 experiments performed in triplicate. (B)Whole cell lysates of HSCs stimulated with PDGF-BB (10ng/ml) at different time points were subject toWestern blot analysis
with speciﬁc antibodies against pY580-SHP-2, pS591-SHP-1, pY536-SHP-1, pPDGFR-β, pERK1/2 and pAkt. The blots were then stripped and reprobed with antibodies directed against the
non-phosphorylated proteins. The results are representative of four experiments performed in triplicate.
A
B
C
Fig. 2. Analysis of the activation and association with the plasma membrane of SHP-2 and SHP-1 in HSCs stimulated with PDGF-BB. (A) Microsomes puriﬁed from HSCs stimulated with
PDGF-BB at different time points were subject to Western blot analysis with speciﬁc antibodies against pY580-SHP-2, and pY536-SHP-1. The blots were then stripped and reprobedwith
antibodies directed against the non-phosphorylated forms of SHP-2 and SHP-1. (B) Microsomes puriﬁed from HSCs stimulated with PDGF-BB for 1 (left panel) or 12h (right panel) were
incubated in the absence (lane 1) or presence ofλPPase (lane 2) or GST-SHP-1/SH2 (lane 3). After each treatment, the samples were centrifuged to separate the pellet (P) from the soluble
fraction (S). The samples were subjected to Western blot analysis with anti-SHP-2 (left panel) and anti-SHP-1 (right panel) antibodies. (C) PDGFR-β immunoprecipitated from
microsomes puriﬁed from HSCs stimulated with PDGF-BB at different time points were subject to Western blot analysis with anti-pY590-SHP-2 (left panel), anti-pY536-SHP-1 (right
panel) and anti-PDGFR-β antibodies (both panels). The blots were stripped and reprobedwith antibodies directed against the non-phosphorylated forms of SHP-2 and SHP-1. The results
are representative of four experiments performed in triplicate.
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phosphatase λPPase to dephosphorylate the proteins contained in the
microsomes or adding the recombinant GST-SHP-1/SH2 domain at a
concentration higher than the afﬁnity range of SHP-2 and SHP-1, and
therefore potentially capable of competing with both phosphatases for
the SH2 anchoring site, we caused a release of two PTPs from the
microsomes (Pellet, in Fig. 2B) into the soluble fraction (Soluble, in
Fig. 2B). This result indicates that SHP-2 and SHP-1 were recruited to
tyrosine phosphorylated proteins in the membrane fraction by means
of their SH2 domains. Furthermore, immunoprecipitation with anti-
PDGFR-β antibody performed on HSC microsomes conﬁrmed theFig. 3.Analysis of the phosphatase activity of SHP-2 and SHP-1 inHSCs stimulatedwith PDGF-BB
tested for the basal tyrosine phosphatase activity in vitro on [32P]phospho-band 3 as detailed in
SSG (promiscuous inhibitors of SHP-2 and SHP-1) or calpeptin, a calpain inhibitor only affecting
panel), 1 h (middle panel) and 12h (bottom panel) were incubated under the conditions detai
evaluated by autoradiography and, after excision of the band 3, by liquid scintillation counting.
3. The ﬁgure is representative of 4 experiments performed in triplicate.ﬁnding elsewhere described [12,13] that SHP-2, and not SHP-1, directly
interacts with the PDGFR-β complex (Fig. 2C, compare left with right
panel). We then wanted to evaluate whether the temporally different
activation of SHP-2 and SHP-1 observed by Western blot analysis also
paralleled the catalytic activity of each phosphatase. To set the
experimental conditions required to distinguish between the activities
of two phosphatases, we adopted the artiﬁce of testing SHP-2 and
SHP-1 immunoprecipitated from HSC whole cell lysate with the
respective antibodies in the presence of promiscuous inhibitors such
asNSC-87877 [35] and sodium stibogluconate (SSG) [36], and calpeptin,
a calpain inhibitor that is also capable of inhibiting SHP-2 [37], using. (A) SHP-2 and SHP-1 immunoprecipitated fromwhole cell lysates of activatedHSCswere
Materials andmethods in the absence and presence of two concentrations of NSC-87877 or
SHP-2 activity). (B) Microsomes puriﬁed fromHSCs stimulatedwith PDGF-BB for 0h (top
led in (A). Samples were then subjected to SDS/PAGE and the remaining radioactivity was
The phosphatase activity is expressed as [32P]phosphate released from [32P]phospho-band
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87877 and SSG affected the catalytic activity of both phosphatases,
albeit SSG proving slightly more effective on SHP-1, only calpeptin
selectively inhibited SHP-2, leaving SHP-1 activity virtually unchanged
(Fig. 3A). As shown in Fig. 3B, the phosphatase activity in the
microsomal fractions, negligible before stimulation with PDGF-BB, was
calpeptin-sensitive, thus SHP-2-dependent at 1 h, but insensitive to
this agent at 12 h, thereby suggesting, albeit not conclusively, that it
might be linked to SHP-1. Taken together, these results strongly suggest
that the regulation of PDGFR-β function in HSC activation is based on
the spatiotemporal distribution of the activated forms of SHP-2 and
SHP-1 [16–23].
3.2. Inhibition of SHP-2 and SHP-1 oppositely affect cell growth in
PDGF-BB-stimulated HSCs
To assess how SHP-2 and SHP-1 are implicated in HSC response to
PDGF-BB stimulation, we knocked down the two phosphatases
separately (Fig. 4A) and examined a time-course analysis of HSC
proliferation. As shown in Fig. 4B, the reduced expression of SHP-2
caused a decrease in cell proliferation by 40% at 48h (left panel),whereas
inhibition in the expression of SHP-1 brought about a 1.5-fold increase in
the cell growth in the early phases of cell proliferation as compared to
the control. The data quantitated as arbitrary units in the histogramsA
B
D
Fig. 4. Effect of down-regulation of SHP-2 and SHP-1 on the cell proliferation of PDGF-BB stimul
SHP-1 siRNAs and control siRNAs and cultured for 48hwere subject toWestern blot analysiswi
ofHSCs transfected as described in (A) and stimulatedwith PDGF-BB at different timepointswa
in triplicate. *P b 0.05; **P b 0.01. (C) The data reported in the histograms in (B) were plotted
transfected as described in (A) and stimulated with PDGF-BB at different time points in the a
was evaluated by BrdU incorporation, quantitated as relative light units per second (rlu/s) andwere then sketched in a graph (Fig. 4C). These experimental conditions
in combination with the use of the SHP-2/-1 inhibitors NSC-87877
and SSG helped further characterize the contribution of the single
phosphatases to HSC proliferation under PDGF-BB stimulation. In fact,
cell proliferation exhibited an overall similar pattern when HSCs were
treated with NSC-87877 (Fig. 4D, upper panels) or SSG (lower panels),
both as such (far-left panels) and after silencing either phosphatase
(middle and far-right panels), reproducing a trend similar to that of
SHP-1 silencing alone (far-right panels). These results also showed that
NSC-87877 and SSG, which scarcely altered the pattern determined by
SHP-1 silencing (far-right panels), totally removed the “braking effect”
of SHP-1 predominating after SHP-2 siRNA treatment, underscoring the
role of SHP-1 as a crucial factor in the control of the amplitude of the
mitogenic response to PDGF-BB (Fig. 5A). This role of SHP-1 was also
evidenced by the expression pattern of cyclin D and p21WAF1, a positive
and a negative cell cycle regulator, [39,40] respectively, with the former
increasing over time after either silencing SHP-2 in the presence of NSC-
87877 or genetic inhibition of SHP-1 alone, and the latter behaving in the
opposite way, as expected (Fig. 5A). As to the early events following
PDGF-BB stimulation, the phosphorylation of PDGFR was not inﬂuenced
by SHP-2 knock-down (Fig. 5B, compare control and SHP-2 siRNA,
left panel), whereas SHP-1 silencing prevented the decrease in the
phosphorylation state of the receptor as observed in the control
(Fig. 5B, compare control and SHP-1 siRNA, left panel), NSC-87877C
atedHSCs. (A)Whole cell lysates of HSCs transfected by nucleofectionwith either SHP-2 or
th anti-SHP-2 (left panel) or with anti-SHP-1 antibodies (right panel). (B) Cell proliferation
s evaluated byBrdU incorporation. The data are themean±SDof 3 experiments performed
as a line graph (○ control, ● SHP-1 siRNA, ■ SHP-2 siRNA). (D) Cell proliferation of HSCs
bsence (○) and the presence of NSC-87877 (●), (upper panel) or SSG (●) (lower panel)
reported as a line graph.
AB
Fig. 5. Effect of down-regulation of SHP-2 and SHP-1 on PDGF-BB-mediated signaling pathways. (A) Whole cell lysates of HSCs transfected with either SHP-2 (3 middle strips) or SHP-1
siRNAs (3 bottom strips) andnegative control siRNAs (3 top strips) and stimulatedwith PDGF-BB (10ng/ml) at different time points in the absence (left panel) or presence (right panel) of
NSC-87877 were subject to Western blot analysis with speciﬁc antibodies against cyclin D and p21 as markers of the cell cycle and β-actin as a loading control. (B) Whole cell lysates of
HSCs transfected with either SHP-2 (6 middle strips) or SHP-1 siRNAs (6 bottom strips) and negative control siRNAs (6 top strips) and stimulated with PDGF-BB (10 ng/ml) at different
time points in the absence (left panel) or presence (right panel) of NSC-87877 were subject to Western blot analysis with speciﬁc antibodies against pPDGFR-β, pERK1/2 and pAkt. The
blots were then stripped and reprobed with antibodies directed against the non-phosphorylated forms of PDGFR-β, ERK1/2 and Akt. The ﬁgure is representative of 4 experiments
performed in triplicate.
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experimental conditions (Fig. 5B, all left panels).
3.3. BA-mediated SHP-1 activation inhibits the cell proliferation of PDGF-BB
stimulated HSCs
Having demonstrated that SHP-1 possesses a key role in modulating
PDGF-BB-mediated signaling by directly acting on the level of PDGFR-β
phosphorylation in activated HSCs, we wondered whether strategies
aimed at enhancing SHP-1 activity could impair PDGF-BB-mediated
proliferation of HSCs. To this aim, we decided to use boswellic acid
(BA), a compound isolated from Boswella serrata with potent anti-
inﬂammatory action and already emerged as capable of inducing the
expression of SHP-1 [26,41]. Such effect was determined by Western
blot analysis with anti-SHP-1 antibody on whole cell lysates from HSCs
previously incubated with different concentrations of BA for 4 h. As
expected, BA increased the expression of SHP-1,whichwas almost totally
abolished by SHP-1 silencing (Fig. 6A, right panels), the protein level of
SHP-2 remaining unaltered by this treatment (left panels). Next, we
veriﬁed the ability of this compound to affect HSC-proliferation by
treating HSC cell cultures with increasing concentrations of BA for 4 h
and stimulating them with PDGF-BB at discrete time points. Fig. 6B
shows that the dose-dependent anti-proliferative action of BA (left
panel), was dramatically counteracted by SHP-1 knockdown (right
panel), which conﬁrms that SHP-1 is chieﬂy targeted by BA and that
HSC proliferation is profoundly affected by SHP-1 expression and activity.Furthermore, the phosphorylation status of PDGFR in HSCs previously
cultured in the presence of 5μM BA for 4h and subsequently stimulated
with PDGF-BB at different time points was shown to be inhibited already
at earlier times (Fig. 6C), which effect was abrogated by SHP-1 siRNA,
underscoring the role of SHP-1 as regulator of the mitogenic function of
PDGFR's downstream signaling pathways.
3.4. Synergistic inhibition of cell proliferation of PDGF-BB-stimulated HSCs
by BA and imatinib
Since the anti-proliferative effects of BA were found to be mediated
by increased expression of SHP-1, which resulted in dephosphorylation
of PDGFR-β, we wondered whether other drugs already known to
inhibit the activation of PDGFR-β could be employed along with BA to
enhance the efﬁcacy of treatment, and thereby contribute to an even
more robust inhibition of HSC proliferation. Among these, we chose
imatinib, the ﬁrst ATP-competitive tyrosine kinase inhibitor, which
was developed to block the chimeric BCR-Abl activity as a front-line
drug in the treatment of chronic myeloid leukemia, also proving to be
effective against other tyrosine kinase receptors, including PDGFR-β
and c-Kit, and to act as an anti-ﬁbrogenic drug [8]. To explore the effects
of the combination of the two compounds, we evaluated the level of
inhibition of PDGF-BB-stimulated HSC proliferation in the presence of
increasing concentrations of one compound as such or associated with
a ﬁxed known sub-inhibitory concentration of the other. As shown in
Fig. 7A, either drug proved efﬁcient in impairing HSC proliferation
AB
C
Fig. 6.Effect of boswellic acid (BA) on the expression of SHP-1 and on cell proliferation in PDGF-BB-stimulatedHSCs. (A)Whole cell lysates of HSCs transfected by nucleofectionwith either
SHP-1 siRNA (right panel) or control siRNA (left panel) and cultured for 4h in the absence or presence of increasing concentrations (1 to 10μM)of BAwere subject toWestern blot analysis
with speciﬁc antibodies against SHP-2 and SHP-1 as well as β-actin as a loading control. (B) HSCs were transfected as described in (A), cultured for 4 h in the absence or presence of
increasing concentrations of BA (■ 1 μM, □2 μM, ● 5 μM) and subsequently stimulated with PDGF-BB (10 ng/ml) at different time points. Cell proliferation of HSCs was evaluated by
BrdU incorporation, quantitated as relative light units per second (rlu/s) and reported as a line graph. (C) Whole cell lysates of transfected HSCs as described in (A), cultured for 4 h in
the absence (left panel) or presence of 5 μM BA (right panel) and subsequently stimulated with PDGF-BB (10 ng/ml) at different time points were subject to Western blot analysis
with anti-pPDGFR-β antibody. The blots were then stripped and reprobed with antibodies directed against the non-phosphorylated form of PDGFR-β. The ﬁgure is representative of 4
experiments performed in triplicate.
295E. Tibaldi et al. / Biochimica et Biophysica Acta 1843 (2014) 288–298only when administered at a concentration as high as 5μM for 48h, the
lower concentrations being virtually inefﬁcient, whereas the association
of 0.5μM imatinib and 0.5 μM BA was able to achieve a signiﬁcant level
of inhibition, indicating that this combination possessed by far a higher
inhibitory potency than the single drugs. Whether this effect was
caused by synergism or additive effect of BA and imatinib was further
investigated by processing the data sketched in Fig. 7A by using the
CompuSys software [28], which determined a Combination Index (CI)
indicative of synergism (CIb1, far right-hand table).We then performed
proliferation time-course assays conducted in the presence of either
inefﬁcacious or drastically inhibitory concentrations (0.5 or 5 μM,
respectively) of BA and imatinib, both used alone, or the combination
of the two drugs able to generate the best value of CI (0.5 μM for each
drug). As shown in Fig. 7B, the synergism was conﬁrmed in the time-
course assay with the most inhibitory effect at 48 h (far right panel),
which was comparable to the higher concentration used for the single
drugs (far left and middle panel). Importantly, the silencing of SHP-1
under these latter experiments abolished the inhibitory effect of thedrug combination (Fig. 7C), further conﬁrming the critical role of SHP-
1 in a signaling axis controlling PDGF-BB-mediated activation of HSC
proliferation and how the synergism of the two drugs can be exploited
in hampering HSC proliferation.
4. Discussion
In this work,we demonstrate that the structurally related SHP-2 and
SHP-1 are both implicated in the regulation of the proliferative signals
downstream of PDGFR-β engagement in HSCs, exhibiting distinct
functions and being activated in a time-dependent manner.
PDGF is themost potentmitogen released upon hepatocyte damage,
contributing to liver ﬁbrosis by targeting its cognate receptor PDGFR at
the surface of HSCs. PDGFR-β, negligible in quiescent HSCs, is rapidly
expressed in response to inﬂammatory stimuli [1–5], triggering
signaling cascades critical for proliferation and ECMdeposition. To fulﬁll
its function, PDGFR-β forms a dimer upon PDGF engagementwith auto-
transphosphorylation at several tyrosine residues, which in turn serve
AB
C
Fig. 7. Effect of the combination of BA and imatinib on cell proliferation of PDGF-BB-stimulatedHSCs. (A) After incubation ofHSCs in the absence or presence of increasing concentrations of
BA (0.1 to 5μM, left histogram) supplementedwithout (gray bars) or with 0.5μM imatinib (white bars) or alternatively in the absence or presence of increasing concentrations of imatinib
(0.1 to 5 μM, right histogram) supplemented without (gray bars) or with 0.5 μM BA (white bars) for 30 min, followed by stimulation with PDGF-BB (10 ng/ml), cell proliferation was
evaluated by BrdU incorporation and quantitated as relative light units per second (rlu/s) after 48 h. The values obtained as BrdU incorporation are expressed as percentage of cell
proliferation relative to non-treated samples. The data are the mean± SD of 4 experiments performed in triplicate. These data were further processed to derive the Combination Index
(CI) for each drug combination (far right-hand table). CI b 1, synergism; 1, additive effect; CI N 1, antagonism. (B) After incubation of HSCs in the absence (○) or presence of increasing
concentrations of BA (■ 0.5, ● 5 μM, far-left panel), imatinib (■ 0.5, ● 5 μM, middle panel) or 0.5 μM of BA and 0.5 μM imatinib (●, far-right panel) for 30min, followed by stimulation
with PDGF-BB (10 ng/ml), cell proliferation was evaluated by BrdU incorporation and quantitated as relative light units per second (rlu/s) at different time points. (C) After incubation
of HSCs transfected by nucleofection with either SHP-1 siRNA (right panel) or control siRNA (left panel) for 4 h in the absence (○) or presence of 0.5 μM of BA supplemented with
increasing concentrations of imatinib (● 0.5, ■ 5 μM) and stimulated with PDGF-BB (10 ng/ml), cell proliferation was evaluated by BrdU incorporation and quantitated as relative light
units per second (rlu/s) at different time points. The data are the mean± SD of 4 experiments performed in triplicate.
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that help propagate early downstream signals as well as activate
delayed negative feedbacks.
The signaling cascades that depend upon PDGFR-β activation are
linked to the level of tyrosine phosphorylation of the receptor itself and
to the balance between, and sometimes even to a parallel contribution
of, tyrosine kinase and tyrosine phosphatase activities. In the case of
HSCs, as in other cell models, PDGFR signaling is positively inﬂuenced
by SHP-2 in the early phases of HSC activation by PDGF-BB engagement,
whereas the signals are terminated by the late activation of SHP-1. In
more detail, SHP-2 becomes activated in the early phase of this process
by binding to PDGFR-β and acting as a downstream effector of this
signaling cascade, eventually bringing about the activation of ERK1/2
and Akt. In addition, SHP-2 silencing, which does not affect PDGFR-β
phosphorylation, reduces ERK1/2 and Akt activation (data not shown)
as well as DNA synthesis in PDGF-BB-stimulated HSCs, which is
consistent with the recognized role of SHP-2 in promoting cell
proliferation and survival [14,18–20]. In contrast, SHP-1 exhibits a
spatio-temporal distribution different from that of SHP-2 in that it doesnot appear to interact with PDGFR-β, instead being activated at a later
stage. PDGFR-β turns out to be a critical target for SHP-1 in HSCs, as is
documented by the dramatic increase of the phosphorylation of
PDGFR-β upon SHP-1 knock-down with the subsequent elevation
of the proliferative and survival molecular markers, such as the
phosphorylated forms of Akt, ERK1/2 and the expression of cyclin D1.
The cellular response to these molecular changes consisting in
accelerated cell proliferation indeed conﬁrms the “braking” effect of
SHP-1 on the signaling pathways activated by PDGF-BB in HSCs, as
already observed for signaling cascades triggered by growth factors in
other cell models [18,20,25–29]. Interestingly, when using NSC-87877,
which indiscriminately inhibits both phosphatases (there exists neither
SHP-1 nor SHP-2 speciﬁc inhibitors at the moment), the net effect that
we have observed is a steep rise in cell proliferation similar to that
achieved by knocking down SHP-1, which is suggestive of the action
of SHP-1 largely outweighing that of SHP-2. These ﬁndings indicate
SHP-1 as a valuable target to be desirably triggered to block HSC
proliferation, in agreement with numerous recent reports that highlight
its role as an off-switch of aberrant signaling pathways in several
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as sorafenib, dovitinib, butein, betulinic acid and BA, have also proved
to increase SHP-1 activity or expression, thereby acting as anti-
proliferative or anti-inﬂammatory agents [42–46,26]. We hereby
demonstrate that BA, which is also known to inhibit the enzymatic
activity of 5-lipoxygenase, topoisomerase 2 and human leukocyte
elastase [47], amongst others, causes an increase in SHP-1 expression,
in turn bringing about dephosphorylation of PDGFR-β and down-
regulation of PDGF-BB-dependent signaling in activated HSCs after
PDGF stimulation. The reversal of such effect by SHP-1 silencing again
highlights the critical negative function of SHP-1 in mediating the
inhibitory action of BA in PDGF signaling, conﬁrming the effects observed
in other studies involving the abovementionedmulti-target compounds
[26]. In this regard, whilst the common approach to attenuate
proliferative and survival signals generated by PDGFR engagement has
been the use of PDGFR-directed inhibitors, such as imatinib, nilotinib,
sorafenib and sunitinib [8–11], BA or other agents capable of switching
off these signaling cascades by alternate mechanisms may serve as new
weapons in the ﬁght against inﬂammatory and proliferative diseases,
not only as such but also in combination with the above mentioned
direct inhibitors. In this study, by using the association of BA and
imatinib, HSC proliferation was markedly impaired by downregulating
PDGF-BB-mediated signaling through a synergistic mechanism, the
same inhibitory effects being attained at a concentration of each
molecule 10-fold lower than for the individual drug in the context of
our experimental conditions. Our data point to the inhibition of
PDGFR-mediated signaling by a drug combination treatment as a
promising strategy in the treatment of liver ﬁbrosis, which would
prove to be beneﬁcial not only by slowing down or arresting the ﬁbrotic
process and but also by reducing the occurrence of drug side effects.
In summary, we present evidence that the proliferative signals
sustained by PDGFR-β engagement in HSCs generate well-
orchestrated parallel pathways involving SHP-2 and -1 with activating
and inhibitory function, respectively, in a spatio-temporal manner.
Moreover, the effect of the combined use of BA, which ampliﬁes the
negative function of SHP-1 on PDGFR-β-dependent signaling, and
imatinib, which directly downregulates PDGFR-β activity, in HSCs
suggests the possibility of new therapeutic strategies that could
implement molecules that affect diverse players of this molecular
circuit, thus paving the way to multi-drug low-dose regimens for liver
ﬁbrosis.
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